

CLAIMS

1. A method for inhibiting neuronal cell death, the method comprising treating neuronal cells with a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof *in vitro*:



(I).

2. Use of a pharmaceutical composition containing a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or treatment of the symptom of mitochondrial dysfunction caused by oxidative stress in central nervous system diseases:




(I),

wherein the central nervous system diseases are selected from the group

consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis**.**

3. Use of a health functional food containing a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or alleviation of the symptom of mitochondrial dysfunction caused by oxidative stress in central nervous diseases:




(I),

wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis**.**


4. A method for inhibiting neuronal cell death, the method comprising treating neuronal cells with a magnesium-serinate compound having the FT-IR

spectrum shown in (a), (b) or (c) below or a pharmaceutically acceptable salt thereof *in vitro*:


(a)



(b)




(c)




.

5. Use of a pharmaceutical composition containing a magnesium-serinate compound having the FT-IR spectrum shown in (a), (b) or (c) below or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or treatment of the symptom of mitochondrial dysfunction caused by oxidative stress in central nervous system diseases**,** wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down’s syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis


(a)



(b)



(c)




.

6. Use of a health functional food containing a magnesium-serinate compound having the FT-IR spectrum shown in (a), (b) or (c) below or a


pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or alleviation of the symptom of mitochondrial dysfunction caused by oxidative stress in central nervous diseases,

wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis


(a)



(b)



(c)


COO⁻ Finger print
NH3⁺ band
3800
3600
3400
3200
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600

.